Larimar Therapeutics, Inc.
LRMRDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 13, 2026
9dMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
Larimar Reports Financial Results
Filed: 2026-08-04 AccNo: 0001193125-26-331516 Size: 19 MB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
SourceLRMR Earnings Report
EPS Est: $-0.39 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How LRMR's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CTI-1601 | Phase 2 | Friedreich Ataxia | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Larimar Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Larimar Therapeutics, Inc.'s (LRMR) pipeline across Phase 2. Its lead program is CTI-1601 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Larimar Therapeutics, Inc.'s next FDA catalyst?→
Larimar Therapeutics, Inc.'s (LRMR) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LRMR biotech catalysts?→
Add LRMR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Larimar Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.